Feezo Chem. Formulation Profile
Key Indicators
- Authorised Capital ₹ 4.00 M
as on 17-06-2024
- Paid Up Capital ₹ 2.30 M
as on 17-06-2024
- Company Age 19 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 18.20 M
as on 17-06-2024
- Satisfied Charges ₹ 1.03 M
as on 17-06-2024
- Revenue -39.09%
(FY 2023)
- Profit 109.96%
(FY 2023)
- Ebitda -30.13%
(FY 2023)
- Net Worth 3.12%
(FY 2023)
- Total Assets -6.92%
(FY 2023)
About Feezo Chem. Formulation
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 4.00 M and a paid-up capital of Rs 2.30 M.
The company currently has active open charges totaling ₹1.82 Cr. The company has closed loans amounting to ₹1.03 M, as per Ministry of Corporate Affairs (MCA) records.
Karan Miglani, Harsh Kumar, Geetika Miglani, and One other member serve as directors at the Company.
- CIN/LLPIN
U24110UP2005PTC029888
- Company No.
029888
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Apr 2005
- Date of AGM
18 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Feezo Chem. Formulation?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Geetika Miglani  | Director | 28-Mar-2006 | Current |
| Karan Miglani | Director | 29-Jun-2012 | Current |
| Harsh Kumar | Director | 28-Apr-2005 | Current |
| Pawan Miglani | Director | 28-Apr-2005 | Current |
Financial Performance and Corporate Structure Insights of Feezo Chem. Formulation.
Feezo Chem. Formulation Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 39.09% decrease. The company also saw a substantial improvement in profitability, with a 109.96% increase in profit. The company's net worth moved up by a moderate rise of 3.12%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Feezo Chem. Formulation?
In 2023, Feezo Chem. Formulation had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 27 Sep 2008 | ₹1.82 Cr | Open |
Others Creation Date: 16 Oct 2017 | ₹1.03 M | Satisfied |
How Many Employees Work at Feezo Chem. Formulation?
Unlock and access historical data on people associated with Feezo Chem. Formulation, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Feezo Chem. Formulation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Feezo Chem. Formulation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
